Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2019
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2019, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline landscape.
Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.c
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 75, 77, 6, 5, 87, 13 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 29, 22, 27, 2 and 1 molecules, respectively.
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2019, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline landscape.
Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.c
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 75, 77, 6, 5, 87, 13 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 29, 22, 27, 2 and 1 molecules, respectively.
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
Appendix
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Companies, H2 2019 (Contd..14), H2 2019
Products under Development by Companies, H2 2019 (Contd..15), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H2 2019
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc, H2 2019
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2019
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Companies, H2 2019 (Contd..14), H2 2019
Products under Development by Companies, H2 2019 (Contd..15), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H2 2019
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc, H2 2019
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2019
LIST OF FIGURES
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
4SC AG
AbbVie Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Aeglea BioTherapeutics Inc
Aileron Therapeutics Inc
Aleta Biotherapeutics Inc
Altor Bioscience LLC
Amgen Inc
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
Apexian Pharmaceuticals Inc
Applied Therapeutics Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
AUM Biosciences Pte Ltd
Autolus Therapeutics Plc
Avalon GloboCare Corp
Ayala Pharmaceuticals Inc
Beam Therapeutics Inc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
Bioceltech Therapeutics Ltd
Biocure Technology Inc
BioSight Ltd
Bristol-Myers Squibb Co
CanBas Co Ltd
CARsgen Therapeutics Ltd
CASI Pharmaceuticals Inc
Cell Medica Ltd
Cellectis SA
Cellestia Biotech AG
Cellipse SAS
Cellular Biomedicine Group Inc
Celularity Inc
Chesapeake Therapeutics LLC
China Immunotech Co Ltd
CRISPR Therapeutics AG
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals Inc
Delta-Fly Pharma Inc
DevaCell Inc
Dialectic Therapeutics Inc
Diazon Pharmaceuticals Inc
DiNonA Inc
Elf Zone Inc
Eli Lilly and Co
Enzyme by Design Inc
Epizyme Inc
Erytech Pharma SA
Eureka Therapeutics Inc
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Felicitex Therapeutics Inc
Formula Pharmaceuticals Inc
Fusion Pharma LLC
Gamida Cell Ltd
GEMoaB Monoclonals GmbH
Generon (Shanghai) Corp Ltd
Genexine Inc
Gilead Sciences Inc
Gmax Biopharm Ltd
Gracell Bio
GT Biopharma Inc
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HemoGenyx LLC
HighPass Bio Inc
Housey Pharmaceutical Research Laboratories LLC
HRAIN Biotechnology Co Ltd
Hummingbird Bioscience Pte Ltd
iCell Gene Therapeutics LLC
iDD biotech SAS
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunoGen Inc
Immunomedics Inc
Immunotech Biopharm Ltd
Inatherys
Incuron LLC
Incysus Therapeutics Inc
Incyte Corp
Innovative Cellular Therapeutics Co Ltd
Interprotein Corp
Jazz Pharmaceuticals Plc
Johnson & Johnson
Juno Therapeutics Inc
Juventas Cell Therapy Ltd
Karyopharm Therapeutics Inc
Kecellitics Biotech Co Ltd
Kronos Bio Inc
LegoChem Biosciences Inc
Les Laboratoires Servier SAS
Lin Bioscience Inc
MAA Laboratories Inc
MacroGenics Inc
Magenta Therapeutics Inc
MannKind Corp
Marker Therapeutics Inc
Medivir AB
Merck & Co Inc
Meryx Inc
Millennium Pharmaceuticals Inc
Miltenyi Biotec GmbH
Molecular Templates Inc
Nanjing Bioheng Biotech Co Ltd
Nanjing Iaso Biotherapeutics Co Ltd
Nanjing KAEDI Biotech Inc
Nanjing Legend Biotech Co Ltd
Nanovalent Pharmaceuticals Inc
NantKwest Inc
Nimbus Therapeutics LLC
Nkarta Inc
Nohla Therapeutics Inc
Novartis AG
NovImmune SA
NovoMedix LLC
Omeros Corp
Oncoceutics Inc
Onconova Therapeutics Inc
OncoTartis Inc
OncoTherapy Science Inc
Orca Biosystems Inc
OSE Immunotherapeutics
Pascal Biosciences Inc
PeproMene Bio Inc
PersonGen Biomedicine Suzhou Co Ltd
Pfizer Inc
Pharma Mar SA
Polyphor AG
Precision Biosciences Inc
Protheragen Inc
PTC Therapeutics Inc
Regenacy Pharmaceuticals LLC
Regeneron Pharmaceuticals Inc
Retrotherapy LLC
Samus Therapeutics LLC
Sanofi
Sareum Holdings Plc
SciTech Development LLC
SELLAS Life Sciences Group Inc
Selvita SA
Senz Oncology Pty Ltd
Shanghai GeneChem Co Ltd
Shanghai Longyao Biotechnology Inc Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shenzhen BinDeBio Ltd
Sian Wuhan Medical Technology Co Ltd
SpecificiT Pharma Inc
Spectrum Pharmaceuticals Inc
Spherix Inc
Sun Pharma Advanced Research Company Ltd
SunRock Biopharma SL
Syndax Pharmaceuticals Inc
SYNIMMUNE GmbH
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
TC BioPharm Ltd
TCR2 Therapeutics Inc
TheraPharm Deutschland GmbH
Tianjin Mycure Medical Technology Co Ltd
Tolero Pharmaceuticals Inc
Trillium Therapeutics Inc
Triphase Accelerator Corp
UWELL Biopharma Inc
Vor BioPharma Inc
Wugen Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xbrane Biopharma AB
Xencor Inc
Zhejiang Teruisi Pharmaceutical Inc
Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd
ZIOPHARM Oncology Inc
Zovis Pharmaceuticals
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
4SC AG
AbbVie Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Aeglea BioTherapeutics Inc
Aileron Therapeutics Inc
Aleta Biotherapeutics Inc
Altor Bioscience LLC
Amgen Inc
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
Apexian Pharmaceuticals Inc
Applied Therapeutics Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
AUM Biosciences Pte Ltd
Autolus Therapeutics Plc
Avalon GloboCare Corp
Ayala Pharmaceuticals Inc
Beam Therapeutics Inc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
Bioceltech Therapeutics Ltd
Biocure Technology Inc
BioSight Ltd
Bristol-Myers Squibb Co
CanBas Co Ltd
CARsgen Therapeutics Ltd
CASI Pharmaceuticals Inc
Cell Medica Ltd
Cellectis SA
Cellestia Biotech AG
Cellipse SAS
Cellular Biomedicine Group Inc
Celularity Inc
Chesapeake Therapeutics LLC
China Immunotech Co Ltd
CRISPR Therapeutics AG
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals Inc
Delta-Fly Pharma Inc
DevaCell Inc
Dialectic Therapeutics Inc
Diazon Pharmaceuticals Inc
DiNonA Inc
Elf Zone Inc
Eli Lilly and Co
Enzyme by Design Inc
Epizyme Inc
Erytech Pharma SA
Eureka Therapeutics Inc
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Felicitex Therapeutics Inc
Formula Pharmaceuticals Inc
Fusion Pharma LLC
Gamida Cell Ltd
GEMoaB Monoclonals GmbH
Generon (Shanghai) Corp Ltd
Genexine Inc
Gilead Sciences Inc
Gmax Biopharm Ltd
Gracell Bio
GT Biopharma Inc
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HemoGenyx LLC
HighPass Bio Inc
Housey Pharmaceutical Research Laboratories LLC
HRAIN Biotechnology Co Ltd
Hummingbird Bioscience Pte Ltd
iCell Gene Therapeutics LLC
iDD biotech SAS
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunoGen Inc
Immunomedics Inc
Immunotech Biopharm Ltd
Inatherys
Incuron LLC
Incysus Therapeutics Inc
Incyte Corp
Innovative Cellular Therapeutics Co Ltd
Interprotein Corp
Jazz Pharmaceuticals Plc
Johnson & Johnson
Juno Therapeutics Inc
Juventas Cell Therapy Ltd
Karyopharm Therapeutics Inc
Kecellitics Biotech Co Ltd
Kronos Bio Inc
LegoChem Biosciences Inc
Les Laboratoires Servier SAS
Lin Bioscience Inc
MAA Laboratories Inc
MacroGenics Inc
Magenta Therapeutics Inc
MannKind Corp
Marker Therapeutics Inc
Medivir AB
Merck & Co Inc
Meryx Inc
Millennium Pharmaceuticals Inc
Miltenyi Biotec GmbH
Molecular Templates Inc
Nanjing Bioheng Biotech Co Ltd
Nanjing Iaso Biotherapeutics Co Ltd
Nanjing KAEDI Biotech Inc
Nanjing Legend Biotech Co Ltd
Nanovalent Pharmaceuticals Inc
NantKwest Inc
Nimbus Therapeutics LLC
Nkarta Inc
Nohla Therapeutics Inc
Novartis AG
NovImmune SA
NovoMedix LLC
Omeros Corp
Oncoceutics Inc
Onconova Therapeutics Inc
OncoTartis Inc
OncoTherapy Science Inc
Orca Biosystems Inc
OSE Immunotherapeutics
Pascal Biosciences Inc
PeproMene Bio Inc
PersonGen Biomedicine Suzhou Co Ltd
Pfizer Inc
Pharma Mar SA
Polyphor AG
Precision Biosciences Inc
Protheragen Inc
PTC Therapeutics Inc
Regenacy Pharmaceuticals LLC
Regeneron Pharmaceuticals Inc
Retrotherapy LLC
Samus Therapeutics LLC
Sanofi
Sareum Holdings Plc
SciTech Development LLC
SELLAS Life Sciences Group Inc
Selvita SA
Senz Oncology Pty Ltd
Shanghai GeneChem Co Ltd
Shanghai Longyao Biotechnology Inc Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shenzhen BinDeBio Ltd
Sian Wuhan Medical Technology Co Ltd
SpecificiT Pharma Inc
Spectrum Pharmaceuticals Inc
Spherix Inc
Sun Pharma Advanced Research Company Ltd
SunRock Biopharma SL
Syndax Pharmaceuticals Inc
SYNIMMUNE GmbH
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
TC BioPharm Ltd
TCR2 Therapeutics Inc
TheraPharm Deutschland GmbH
Tianjin Mycure Medical Technology Co Ltd
Tolero Pharmaceuticals Inc
Trillium Therapeutics Inc
Triphase Accelerator Corp
UWELL Biopharma Inc
Vor BioPharma Inc
Wugen Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xbrane Biopharma AB
Xencor Inc
Zhejiang Teruisi Pharmaceutical Inc
Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd
ZIOPHARM Oncology Inc
Zovis Pharmaceuticals
